Description

Pemvidutide (ALT-801) is a novel investigational peptide designed as a dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). This unique pharmacological profile distinguishes it from conventional GLP-1 analogs by providing complementary metabolic effects, making it highly valuable for research in non-alcoholic steatohepatitis (NASH), obesity, and metabolic disorders.

Research has shown that Pemvidutide promotes marked body weight loss, reduces hepatic fat content, and improves lipid and glycemic profiles, reflecting its dual-action engagement with metabolic pathways. The GLP-1R activation provides satiety enhancement, appetite suppression, and improved insulin sensitivity, while the GCGR agonism promotes increased energy expenditure and lipid mobilization.

Pemvidutide’s dual mechanism provides a balanced approach to metabolic regulation, offering a stronger efficacy profile compared to GLP-1 mono-agonists in experimental models. This compound is currently under investigation for its potential role in addressing conditions such as obesity-related complications, insulin resistance, hepatic steatosis, and cardiovascular risk markers.

Produced in a GMP-certified facility, Pemvidutide is supplied as a high-purity research-grade peptide. The compound is suitable for preclinical laboratory studies, peptide pharmacology investigations, and exploratory studies in metabolic regulation.

For laboratory research use only. Not intended for human or veterinary applications.

Product Specifications

Mechanism of Action & Research Applications

Pemvidutide operates as a dual GLP-1R and GCGR agonist, engaging two distinct but complementary receptor pathways:

• GLP-1R Activation: Enhances insulin secretion, suppresses glucagon release, delays gastric emptying, and promotes satiety. These effects collectively contribute to reduced food intake, improved glucose control, and body weight management in experimental studies.

• GCGR Activation: Stimulates energy expenditure, enhances lipid oxidation, and mobilizes fatty acids. This helps reduce hepatic lipid accumulation and supports research in non-alcoholic fatty liver disease (NAFLD) and NASH.

By combining these effects, Pemvidutide exhibits a synergistic profile, achieving greater reductions in body weight, liver fat, serum triglycerides, and cholesterol levels compared to GLP-1 analogs alone.

Research Applications:

• Obesity research: Demonstrating sustained body weight reduction and appetite suppression.

• NASH and NAFLD research: Significantly decreasing liver fat and fibrosis markers.

• Lipid metabolism studies: Improving lipid profiles and reducing cardiovascular risk factors.

• Glucose homeostasis: Enhancing insulin sensitivity and glycemic control.

• Pharmacology studies: Evaluating the efficacy of dual agonist strategies in peptide therapeutics.

These properties make Pemvidutide a promising research tool for investigating novel therapeutic strategies in metabolic diseases.

Side Effects (For Reference in Models)

In laboratory studies and preclinical research models, the following observations have been reported:

• Gastrointestinal effects: Nausea, vomiting, or diarrhea (common with GLP-1R agonists).

• Metabolic adjustments: Transient increases in energy expenditure and glucose metabolism.

• Hepatic markers: Shifts in liver enzyme activity during lipid mobilization studies.

• Endocrine balance: Possible transient changes in insulin and glucagon ratios.

These effects are typically dose-dependent and consistent with GLP-1/GCGR dual agonist pharmacology.

Note: Side effects described here are derived from laboratory and preclinical models. Pemvidutide is provided strictly for research use only and not for medical or veterinary application.

Disclaimer

Pemvidutide (ALT-801) is offered in high purity and manufactured under GMP standards for research purposes only. It is not intended for human consumption, medical treatment, or diagnostic use. For laboratory research use only.

Keywords

• CAS 2538014-94-5

• GLP-1R/GCGR dual agonist peptide

• Pemvidutide obesity research

• Pemvidutide NASH research

• GMP peptide supplier

• Pemvidutide wholesale

• Buy Pemvidutide peptide

• High purity research peptide ALT-801

• Laboratory peptide for metabolic research